PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25322286-3	2014	RESULTS: Fast metabolizers (CYP3A5*1/POR*28T carriers) had two-fold to three-fold higher tacrolimus dose requirements compared with slow metabolizers (CYP3A5*3/*3/CYP3A4*22 carriers) and needed significantly more time to achieve the target tacrolimus C0 of a minimum 10 ng/ml (3.3+-1.7 vs. 1.34+-0.75 days; P<0.0001).	Tacrolimus	89-99	cytochrome p450 oxidoreductase	Homo sapiens	37-40	
25322286-6	2014	Multivariate analyses identified the CYP3A5*1/POR*28/CYP3A4*22 genotype combination as the single strongest determinant of tacrolimus dose requirements throughout the first year, explaining between 24-40% of its variability, whereas recipient age, hematocrit, and delayed graft function were additional nongenetic determinants of tacrolimus dose.	Tacrolimus	123-133	cytochrome p450 oxidoreductase	Homo sapiens	46-49	
25322286-7	2014	CONCLUSION: Combining the CYP3A5*1, POR*28 and CYP3A4*22 genotypes allows partial differentiation of early tacrolimus dose requirements and the time to reach therapeutic target concentrations after transplantation, but without obvious clinical implications.	Tacrolimus	107-117	cytochrome p450 oxidoreductase	Homo sapiens	36-39